As both SRC and MCL-1 are important in the etiology of multiple cancers [26, 27], we used publicly available data to identify additional cancer contexts where a combined SRC and MCL-1 inhibitor strategy may be effective, identifying PDAC as possibly responsive to a dual SRC and MCL-1 inhibitor therapeutic strategy. The gene discussed is SRC; the disease is cancer.